作者: Justin Stebbing , Keren Paz , Gary K. Schwartz , Leonard H. Wexler , Robert Maki
DOI: 10.1002/CNCR.28696
关键词:
摘要: BACKGROUND: Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from few standard-of-care therapeutics available is small. The rarity of this tumor, combined wide range subtypes, leads to difficulties in conducting clinical trials. authors previously reported outcome patients variety common solid tumors who received treatment drug regimens that were first tested patient-derived xenografts using proprietary method ("TumorGrafts"). METHODS: Tumors resected 29 implanted into immunodeficient mice identify targets drugs for use. results sensitivity testing TumorGrafts used personalize cancer treatment. RESULTS: Of tumors, 22 (76%) successfully engrafted, permitting identification these patients. Although 6 died before completion TumorGraft testing, correlation between was observed 13 16 (81%) remaining individuals. No progressed during TumorGraft-predicted therapy. CONCLUSIONS: current data support use personalized model as an investigational platform therapeutic decision-making can guide rare such sarcomas. A randomized phase 3 trial versus physician's choice warranted.